Two years follow-up of an open-label pilot study of treatment with rituximab in patients with early diffuse cutaneous systemic sclerosis.
Karin MelsensEls VandecasteeleEllen DeschepperValérie BadotDaniel BlockmansGuy BrusselleEllen De LangheMichel De PauwClaire DebusschereSaskia DecumanLiselotte DerooFrédéric HoussiauJan LenaertsYves PietteKristof ThevissenMarie VanthuyneRené WesthovensSara WijnantFilip De KeyserVanessa SmithPublished in: Acta clinica Belgica (2017)
This is the first multicentre Belgian collaboration investigating potential efficacy of rituximab in early dcSSc. Rituximab appears to be safe and tolerable and it may have beneficial effects on skin involvement, on overall disease activity and on stabilization of internal organ status in early dcSSc.
Keyphrases
- systemic sclerosis
- disease activity
- diffuse large b cell lymphoma
- rheumatoid arthritis
- systemic lupus erythematosus
- interstitial lung disease
- hodgkin lymphoma
- ankylosing spondylitis
- chronic lymphocytic leukemia
- clinical trial
- study protocol
- randomized controlled trial
- juvenile idiopathic arthritis
- wound healing
- high grade
- risk assessment
- soft tissue
- climate change